objective. To characterize the clinical outcomes of patients with bloodstream infection caused by carbapenem-resistant Acinetobacter baumannii during a 2-state monoclonal outbreak.
1
Infections attributable to drug-susceptible Acinetobacter isolates are commonly treated either with the combination ampicillin-sulbactam or with carbapenems; however, one of the most alarming characteristics of A. baumannii is its ability to become highly resistant to all antibiotics, including carbapenems. 2, 10 Polymyxins, and less frequently tigecycline, have retained in vitro activity against multidrug-resistant isolates. Nevertheless, during the past few years, strains resistant to colistin have been identified, mostly in Asia. 5 Acinetobacter isolates that are resistant to all antibiotics, including polymyxins, are described as extremely drug resistant or XDR. 2, 5 7 This strain of A. baumannii produced a chromosomal and plasmid-encoded OXA-40 carbapenemase that, to our knowledge, constituted the first description of its kind in the United States. This enzyme conferred resistance to all b-lactams, resulting in A. baumannii isolates that were susceptible only to colistin or, in some cases, only to colistin and tigecycline. We describe the clinical presentation and outcomes of patients with bloodstream infection caused by carbapenem-resistant A. baumannii during this outbreak.
methods
A retrospective chart review was performed at 4 tertiary care hospitals and a long-term acute care hospital. Institutional review board approval was obtained. A case was defined as any patient who had carbapenem-resistant A. baumannii (CRAB) recovered from at least 1 blood culture during the period January 1, 2005, through April 30, 2006. Cases were identified using the clinical microbiology laboratory databases at each participating institution. Antimicrobial susceptibilities were determined using the institutions' individual methodology.
Data collected included age, sex, admission and discharge dates, death during hospitalization, surgical procedures, and ICU stay. Comorbidities included diabetes, hypertension, liver cirrhosis, renal insufficiency, dialysis, human immunovirus infection, transplant recipient and immunosuppressive treatment, neutropenia (absolute neutrophil count more than 500 cells/mm), malignancy, decubitus ulcers, tracheostomy, use of mechanical ventilator, septic shock, and anoxic encephalopathy. First day of bacteremia (FDOB) was defined as the first day that CRAB was isolated in blood cultures, taking into account the date of collection. Variables specific to FDOB included location within an ICU; presence, location, and day of placement of a central vascular catheter; and signs of fever and/or hypotension. The variable days to first positive blood culture result was defined as the number of days from admission until FDOB. In addition, the variable days of bacteremia was the number of consecutive days that blood cultures remained positive for CRAB.
Deidentified data were collected on a standardized form and were entered onto spreadsheets (Excel 2007; Microsoft). Categorical variables were analyzed with univariate logistic regression. Continuous variables were assessed for normality and either were log-transformed or were stratified into dummy variables for logistic regression. The Bonferroni adjustment was used with greater than 2 dummy variables. Variables with a P value of .10 or less in bivariate analyses were included in the final multivariate model; however, those with missing data were excluded. Stata, version 10.1 (StataCorp), was used for the statistical analysis.
results
We identified a total of 86 patients with CRAB bloodstream infection during the 16 months of the study (Table 1) . At initial positive blood culture result, 64 patients (74%) were On the FDOB, a total of 53 patients (62%) grew both CRAB and additional pathogens in their blood cultures. One coinfecting organism was observed in 37 patients (43%), 2 were observed in 14 patients (16%), and 3 were observed in 2 patients (2%). Of the 71 copathogens, 19 (27%) were coagulase-negative staphylococci, 17 (24%) were gram-negative bacilli (5 Pseudomonas species, 4 Enterobacter species, 4 Klebsiella species, and 4 other gram-negative bacilli), 14 (20%) were Enterococcus faecalis, 6 (8%) were Enterococcus faecium, 6 (8%) were Enterococcus species, 1 (1%) was Corynebacterium species, 1 (1%) was Streptococcus viridians, and 4 (6%) were Candida species. Only 3 copathogens (4%) were methicillin-resistant Staphylococcus aureus. We did not observe a difference in the type of copathogens during the study period (data not shown).
CRAB was recovered from clinical cultures of respiratory secretions from 29 (34%) of the 86 study patients. Other sources from which CRAB were recovered included wound specimens (17 isolates), catheter tips (17), urine specimens (10), rectal specimens (4), and gastrostomy tube sites (2) . Among these isolates, no clinical differentiation between colonization or infection was made.
Mortality
A total of 35 patients (41%) died. None of the solid-organ transplant recipients or patients identified as immunosuppressed survived ( ). The bivariate analyses with morn p 5 tality as the outcome (Table 2 ) revealed an increased risk of death with an ICU stay; medical ICU patients had a significantly increased risk, compared with the risk of patients housed in other ICUs. The presence of a malignancy and the presence of fever and/or hypotension on the FDOB also were associated with a higher mortality; malignancy had the highest odds ratio (7.259). Other comorbidities, such as mechanical ventilation or renal failure, failed to show a correlation with mortality. There was a trend toward survival with a line change or presence of decubiti and a trend toward death in patients with septic shock. Younger age was associated with increased survival. Interestingly, type of antibiotics received before or after FDOB failed to affect mortality. Multivariate analysis (Table 2) revealed that septic shock, fever and/or hypotension, ICU stay, and increasing age were associated with death, in descending magnitude of risk. A trend for increased survival was noted for patients with decubiti.
Of the 35 patients who died, 19 (54%) had positive blood culture results within 24 hours of their death: 13 patients (37%) had cultures that grew CRAB, and 6 patients (17%) had cultures that grew other pathogens (3 gram-negative bacilli, 1 E. faecium isolate, 1 E. faecalis isolate, and 1 coagulasenegative Staphylococcus isolate). Of the 13 patients with CRAB bacteremia 24 hours before death, 5 had additional copathogens (2 Pseudomonas species, 2 Enterococcus species, and 1 Candida species). Additionally, mortality did not differ between patients on the basis of the presence of CRAB in sources other than blood.
After the FDOB, only 18 patients (21%) received colistin; this antibiotic was given to only 2 patients within 48 hours after the initial blood sample was obtained. Both patients treated empirically with colistin died. After the FDOB, only 12 patients (14%) received tigecycline; this antibiotic was given to only 3 patients within 48 hours after the initial blood sample was obtained. Only 1 patient treated empirically with tigecycline survived (data not available in 1 patient).
Number of Positive Blood Culture Results per Patient
Fifty-seven patients (66.2%) had a single blood culture positive for CRAB, and only 10 failed to have follow-up blood cultures. The bivariate analyses with number of blood cultures positive for CRAB as the outcome (Table 3) revealed that the presence of decubiti was the sole factor significantly associated with having a single blood culture positive for CRAB. In contrast, characteristics associated with having multiple blood cultures positive for CRAB included male sex, renal replacement therapy (intermittent hemodialysis or continuous replacement), an ICU stay, having a central venous catheter changed, and increased length of stay after the first positive culture result. Solid-organ transplant patients and other immunosuppressed patients and those having surgery showed a trend toward having multiple positive blood culture results. Interestingly, although an ICU stay was associated with having multiple positive culture results, patients in the medical ICU showed a trend toward having a single positive culture result.
To evaluate the epidemiology of CRAB bloodstream infections over time, we divided the duration of the study into 3 periods of approximately 6 months each. Over time there was a decrease in the number of patients with single positive blood culture results (from 72% to 54%) and an increase in the number of patients with multiple positive blood culture results (from 28% to 46%). We did not observe a change in the mortality rate throughout the 3 periods (data not shown).
The multivariate model (Table 3) had no significant risk factors associated with having only a single positive blood culture result. Organ transplant recipients and those considered immunosuppressed, male sex, and increased length of stay after the first positive culture result were all associated with having multiple positive culture results; there was a less significant association with renal replacement therapy.
A total of 11 patients (13%) had positive blood culture results that occurred over 10 or more days, and 4 (5%) were bacteremic for more than 30 days (range, 36-86 days). Three of these 4 long-term bacteremic patients were in the burn ICU, and 2 eventually died, with CRAB obtained from culture of blood samples at the time of death.
Antibiotic Susceptibilities
All isolates were imipenem resistant ( ) or intermen p 84 diately susceptible ( ) (Table 4) . None of the 36 CRAB n p 2 isolates tested against ciprofloxacin was susceptible, and only 3 of 77 were susceptible to amikacin. Colistin and tigecycline susceptibilities were tested in 14 and 8 isolates, respectively.
discussion
In 2005, Chicago and neighboring northwest Indiana experienced a multicity outbreak of bacteremia attributable to a monoclonal OXA-40-producing strain of CRAB. 7 We were able to identify, among 4 academic hospitals and 1 long-term acute care hospital, 86 patients with at least 1 blood culture positive for CRAB. The crude hospital mortality rate was 41%, and 37% of patients who died had blood cultures positive for CRAB at the time of death. Independent risk factors for mortality were septic shock on the FDOB and fever and/or hypotension on the FDOB. Location of the patients on the FDOB, either at an acute care hospital or at a long-term acute care hospital, failed to influence mortality.
Most isolates were resistant to all available antimicrobials except colistin or, in some cases, except colistin and tigecycline. Susceptibility testing for these antibiotics was performed in only a subset of our isolates. CRAB isolates from 3 of the 5 centers that participated in this study were identified as OXA-40 producers, as reported elsewhere. 7 Receipt of any type of antibiotic, including colistin, did not alter mortality. Because adequate empirical therapy with either colistin or tigecycline occurred in only 5 patients (6%), 3 of whom died during hospitalization, we cannot say that appropriate empirical therapy was beneficial.
During the outbreak, we noted clinical and epidemiologic differences between patients who had CRAB isolated from a single blood culture and patients who had CRAB isolated from multiple blood cultures. Sixty-six percent of patients had only a single positive blood culture result, despite the lack of treatment with appropriate antibiotics. The presence of decubitus ulcers was the only factor associated with a single positive blood culture result. On the basis of the presence of decubiti, we hypothesize that these single episodes represent specimen contamination or transient bacteremia among patients at risk of skin colonization. Even though it is not fully described in the literature, skin colonization with CRAB was a fairly common observation during the outbreak. Additionally, patients with a single positive blood culture result were more likely to have polymicrobial blood cultures on the FDOB than were patients with multiple positive blood culture results (data not shown). Interestingly, mortality did not differ between patients with a single positive result and patients with multiple positive results, probably reflecting the severity of illness among the study population and their multiple comorbidities, which were more important in determining patient outcome than was CRAB bacteremia.
We noted a transition from a single positive result to multiple positive blood culture results during the study period. This pattern is similar to what was previously described with vancomycin-resistant enterococci in the Chicago area, suggesting an evolution from a mere contaminant to a more pathogenic organism over time. 11 However, no obvious change in mortality was associated with this shift.
Copathogens were identified on the FDOB in 53 cases (62%), the most frequent organisms being enterococci (36%), coagulase-negative staphylococci (27%), and gram-negative rods (24%). This again would suggest some level of contamination of the blood culture samples. Of note, data on the source of the blood samples (peripheral access vs central line access) were not collected. Mortality rates in patients with CRAB have been reported in the range of 52%-60.7%, which is higher than the mortality rate in our group. [12] [13] [14] [15] Furthermore, to our knowledge, our study describes the largest cluster of CRAB bloodstream infections reported to date. The risk factors for mortality that we were able to identify (older age and immunosuppression) are concordant with previous findings. Four patients had persistent CRAB in their blood cultures for up to 84 days; 3 were burn patients in the same burn ICU and 2 eventually died while positive for CRAB on culture. One of these patients also had Pseudomonas aeruginosa recovered from culture of a blood sample at the time of death. Survival during this long period of bacteremia, in such an inmunocompromised population, suggests a low level of virulence, repeated contamination from heavy skin colonization, or sequential infected lines.
In addition to being limited by its retrospective nature, our study is limited by the lack of severity scores (ie, Acute Physiology and Chronic Health Evaluation score); however, we collected and analyzed data on several relevant comorbidities, including mechanical ventilation, tracheostomy, and malignancies. Except for immunosuppression associated with transplantation, no comorbidities were associated with mortality. This study also lacks a control population, thus limiting our conclusions. Furthermore, characterization of bloodstream infections into primary or secondary was not performed. Given the retrospective nature of this study, the number of days of bacteremia was a function of the number of blood culture results obtained by the managing clinical teams, which therefore constitutes another potential confounder.
We consider our study to be unique for several reasons. We evaluated a cohort of patients during the peak of a large monoclonal outbreak of OXA-40-producing CRAB bacteremia in 2 states. This study describes 2 distinct patterns of bloodstream infection with CRAB-patients who have a single positive culture result and patients who have ongoing, often prolonged, bacteremia. Additionally, we described the presence of very prolonged bacteremia in 3 burn patients. Given the spread of Acinetobacter across ICUs worldwide, further prospective studies are necessary to deepen our knowledge of the clinical pathogenicity of this important organism.
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